RE: Re: All basis covered18 Jun 2019 19:44
The fda rejected Arpida application due to inferior efficacy in comparison with another AB and not the liver toxicity...please get your facts right before posting here.
http://www.bioworld.com/content/fda-rejects-arpidas-iclaprim-company-seeks-partner-0
The fda never rejected motif application but asked for more data with regard liver enzymes/Dili to approve Iclaprim.
Motif Iclaprim application passed all fda requirement including its superiority in efficacy and nil nephrotoxicity in comparison to Vancomycin.
Please write here facts and your opinion negative or positive but based on facts not fabrication.
Many holders here are anxious and understandably so about their financial commitment here.
FUNDING,PARTNERSHIPS,TAKEOVER,RIGHT ISSUES. ARE MORE RELEVANT
I myself waiting further clarifications from motif of their βall bases are covered and clear pathwayβ but others here ,may be wiser, think no need yet.
Sitting and waiting patiently and remain hopeful .